ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

California approves $3 billion program for stem-cell research.

November 5, 2004

NCI Implements Changes To Speed Up New Drug Development; compounds In Pipeline Listed

July 9, 1976

Carroll Named Deputy Director At Huntsman; Pamer Leads Infectious Disease Service, MSKCC.

September 29, 2000

LDK378 Demonstrates 58 Percent Overall Response Rate in Phase I

April 25, 2014

Research Dollars Save Money, Lives, Scientists Tell Senate

May 3, 1991

In Brief: Survey Finds Most Localities Have Smoking Limits; Martocchio, Rickel ONS Award Speakers

April 24, 1987